Iambic Therapeutics: CEO Miller Thomas F. received 925,400 shares

What happened Miller Thomas F., CEO, received 925,400 shares on Oct 14, 2026 through two grant transactions: 132,200 shares acquired at $0 and 793,200 shares reported as a derivative award at $0 (total value reported $0).

Key details

• Transaction date and price: Oct 14, 2026 — 132,200 shares @ $0 (award); 793,200 shares @ $0 (award, derivative).
• Shares owned after the transaction: not reported in the filing.
• Footnotes from the filing:
  • F1: The reported shares are represented by restricted stock units, or RSUs, which vest as follows: 25% of the RSUs vest on Sep 10, 2027 and the remaining RSUs vest in twelve equal quarterly installments beginning on Dec 10, 2027.
  • F2: Twenty-five percent of the shares subject to the option vest on Oct 14, 2027 and 1/48th of the shares vest monthly thereafter.
• Filing date: Oct 16, 2026 (transaction reported for Oct 14, 2026); filing was timely.

Why it may matter The filing reports an award of RSUs and a derivative award subject to a vesting schedule; the filing does not show why the insider traded or why the company acted.